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Expanding Our Understanding Minireview
of Polyglutamine Diseases
through Mouse Models
Purkinje cells have moved to the molecular layer (likely
in an attempt to preserve synapses). Immunolocalization
studies show that mutant ataxin-1 localizes to ubiquitin-
positive nuclear inclusions (NIs) in the Purkinje cells of
82Q transgenic mice, as it does in affected neurons in
Xi Lin, Christopher J. Cummings, and Huda Y. Zoghbi*
Howard Hughes Medical Institute
Department of Pediatrics and
Department of Cellular and Molecular Biology
Baylor College of Medicine
SCA1 patients (Skinner et al., 1997). These NIs appearHouston, Texas 77030
in 82Q mice as early as 3.5 weeks and are detectable
in 90% of the Purkinje cells by 12 weeks. Cell death
becomes significant only after 6 months of age, longThe polyglutamine neurodegenerative diseasesÐa group
after the phenotype has appeared. The axons of thethat so far includes spinobulbar muscular atrophy
murine Purkinje cells are not dilated like the human(SBMA), Huntington's disease (HD), dentatorubropalli-
SCA1-affected cells, but this is the only pathologic dif-doluysian atrophy (DRPLA) and the spinocerebellar
ference between the two. The B05 mice thus provide aataxias (SCA1, 2, 3, 6, and 7)Ðresult from the expansion
reliable animal model for SCA1Ðbut leave unansweredof an unstable CAG trinucleotide repeat coding for poly-
the question whether it is the full-length mutant proteinglutamine tracts in the respective proteins. The CAG
or merely the expanded glutamine repeat that inducesrepeat tracts are polymorphic and vary in their instability:
polyglutamine diseases.the SCA7 gene, for example, may expand by hundreds of
Polyglutamine Tract or Full-Length Protein?repeats in one intergenerational transmission, whereas
The first attempts to answer this question were to comethe SCA6 gene is relatively stable and the difference in
from SCA3 transgenic mice. SCA3, also known as Ma-length between the wild-type and mutant CAG tract is
chado-Joseph Disease (MJD), is similar to SCA1 exceptonly three repeats. But in all these diseases, triplet re-
that dentate neurons, rather than Purkinje cells, are thepeats exceeding their normal range cause progressive
primary sites of cerebellar pathology. Basal ganglianeuronal dysfunction and death within 10±20 years after
involvement is also prominent. Ikeda and colleaguesthe onset of symptoms, with longer repeat tracts caus-
(1996) used Pcp2/L7 to generate transgenic mice ex-ing earlier age of onset and more severe disease. Curi-
pressing either full-length or truncated versions ofously, only a specific subset of neurons is vulnerable in
ataxin-3. Mice expressing full-length ataxin-3 with 79each of these diseases, despite the ubiquitous expres-
glutamines, designated MJD79, developed no ataxia orsion of the relevant disease proteins throughout the brain
pathological changes; neither did Q35C mice, which ex-and other tissues. The normal functions of these proteins
pressed a truncated form of ataxin-3 with a CAG tractremain a mystery, except for the androgen receptor
of 35 repeats. In contrast, both Q79C mice (carrying(SBMA) and the a1A voltage-dependent calcium channel
truncated ataxin-3 with 42 amino acids C terminal to a(SCA6). The importance of mouse models for studying
CAG tract of 79 repeats) and Q79 mice (bearing a peptidepolyglutamine pathogenesis will become apparent after
containing 79 glutamines) became ataxic by 4 weeks ofa brief look at the issues that have become clearer, and
age. By 8 weeks, Q79C mice showed massive degenera-in some cases more complex, through their use.
tion of all three layers of the cerebellum, which wasThe First Mouse Model for a Polyglutamine Disease
reduced to about one-eighth of its normal volume.Cerebellar atrophy with severe Purkinje cell degenera-
It is noteworthy that the expanded polyglutamine tract
tion is responsible for the SCA1 ataxic phenotype
is sufficient to cause neuronal death, and that its toxicity
(Zoghbi and Ballabio, 1995). Wanting to study the Pur-
causes massive cell loss as opposed to the more pro-
kinje cell pathology at the root of this disease, Burright gressive dysfunction seen, for example, with ataxin-1.
et al. (1995) expressed full-length human SCA1 cDNAs Ikeda and colleagues (1996) proposed that cell-specific
with different numbers of CAG repeats in Purkinje cells proteolytic cleavage of the mutant protein frees the toxic
using a Purkinje cell±specific promoter from the Pcp2/ polyglutamine tract, which then induces cell death.
L7 gene. The resulting mice highly express either a wild- There is no evidence yet, however, that ataxin-3 cleav-
type SCA1 allele with 30 repeats (30Q) or an expanded age occurs in affected brain regions of MJD/SCA3 pa-
allele with 82 repeats (82Q). The 30Q mice are indistin- tients. Moreover, it is impossible to conclude that full-
guishable from wild-type littermates, but adult 82Q mice length ataxin-3 is not toxic without data on transgene
(known as the B05 line) develop severe ataxia and pro- expression levels from this series of mice.
gressive Purkinje cell pathology (Clark et al., 1997). During the same period, Mangiarini and colleagues
The first histologic abnormalities, detectable at P25, (1996) generated mice using a 1.9 kb human genomic
are cytoplasmic vacuoles. Loss of proximal dendritic fragment containing huntingtin (HD) 59 flanking se-
arborization and dendritic spines becomes apparent at quences and exon 1 with an unstable expanded CAG
5 weeks when the mice begin to show mild difficulty on tract of z130 repeats. The R6/2 line (with 144 repeats)
the rotating rod; by the time 82Q mice are overtly ataxic ubiquitously expresses the first 69 amino acids of hun-
(12±15 weeks), the dendritic arborization is mostly lost, tingtin with the elongated CAG tract at lower-than-
the molecular layer is atrophied, and some heterotopic endogenous levels. Expecting to study CAG repeat in-
stability in the mouse, the investigators were somewhat
surprised to discover that this small fragment was* To whom correspondence should be addressed (e-mail: hzoghbi@
bcm.tmc.edu). enough to create a progressive neurological phenotype
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comprising some HD-like features. R6/2 mice are indis- the HPRT protein (only 48 kDa with the polyglutamine).
The full protein context may mitigate the toxicity of antinguishable from nontransgenic littermates at weaning,
but at 9±11 weeks show handling-induced seizures, limb expanded tract, slowing symptom onset; it may also
lead to gains of function through new protein±proteindyskinesia that progresses to reflexive clasping of the
limbs to the body when suspended, tremor, and stereo- interactions, thereby mediating selective toxicity.
Nuclear Inclusions Revisitedtypic involuntary movements. As the disease worsens,
the mice unaccountably lose body weight, develop uri- The finding that, in transgenic mice, huntingtin localizes
to nuclear inclusions (Vonsattel and DiFiglia, 1998) rekin-nary incontinence and unusual vocalizations, and die
suddenly of unknown causes between 10 and 13 weeks. dled interest in similar observations made 20 years pre-
viously in human HD patients. Is the fact that NIs appearDespite the neurologic signs, neuropathology revealed
only that R6/2 brains are consistently smaller than nor- not only in HD but in SBMA, SCA1, SCA3, SCA7, and
DRPLA patients significant (Paulson, 1999)? It seemsmal and develop NIs throughout the CNS, prior to any
neurobehavioral changes. These amembranous NIs show intuitive that insoluble aggregates might disrupt nuclear
functions. But it is equally conceivable that NIs mighta filamentous morphology by electron microscopy (EM)
and stain positively for ubiquitin (Davies et al., 1997). benefit the cell by sequestering the mutant proteins.
Consistent with this latter possibility is the finding that,None of the neurodegeneration typical of HD is appar-
ent; it may be that the mice do not live long enough to in the mouse model expressing full-length HD, NIs ap-
pear in several brain regions typically spared in HD (e.g.,develop HD pathology. It is somewhat surprising that
R6/2 mice show some features typical of HD, since the Purkinje cells). In fact, the frequency of inclusions is
,1% in the striatum, where apoptosis is most conspicu-transgene codes for only 3% of huntingtin. Does the
truncated peptide retain the full-length protein's ability ous (Reddy et al., 1998).
Is the nuclear location of the protein significant? Work-to interact with certain cell-specific factors, or does the
expanded polyglutamine tract produce a generalized ing with SCA1 models, Klement et al. (1998) set out to
determine if ataxin-1 must be in the nucleus to causetoxicity that overlaps with some features of HD?
To see whether any gene with an expanded CAG re- disease. They generated transgenic mice that express
expanded ataxin-1 (82 glutamines) with a mutated nu-peat might cause pathology, Ordway and colleagues
(1997) introduced a 146-unit repeat into the mouse hypo- clear localization signal (NLS), causing ataxin-1 to re-
main diffusely distributed throughout the cytoplasm. Al-xanthine phosphoribosyltransferase (Hprt) gene. These
knockin mice, like the R6/2, acquire seizures, tremors, though these mice express ataxin-1 in Purkinje cells at
levels comparable to those observed in the originaland die prematurely; they also develop NIs, without neu-
rodegeneration. In contrast to the R6/2 line, however, SCA1 (82Q) transgenic mice, they develop neither Pur-
kinje cell pathology, motor dysfunction, nor aggregates.they gain weight. The expanded polyglutamine tract is
clearly toxic independent of protein context, but it Nuclear localization of ataxin-1 is thus critical for patho-
genesis and for aggregation.seems that context mediates the phenotypic differences
and selective neuronal vulnerability of the polyglutamine But are pathogenesis and aggregation necessarily
linked? Klement et al. (1998) characterized transgenicdiseases.
Further support for this hypothesis comes from mice mice that express mutant ataxin-1 (77Q) lacking the self-
association region, found to be essential for ataxin-1generated by Reddy and colleagues (1998), who ex-
pressed full-length HD cDNA with 16, 48, or 89 CAG dimerization. These mice develop ataxia and Purkinje
cell pathology similar to 82Q mice, but without apparentrepeats at high (two to five times endogenous) levels
under the control of a cytomegalovirus promoter. Mice nuclear ataxin-1 aggregation. Deletion of 122 amino
acids could compromise the protein in various wayswith 48 or 89 repeats develop progressive neurobehav-
ioral abnormalities. At 8 weeks, they begin clasping; at (folding, turnover rate, interactions), but this truncated
ataxin-1 retains its ability to interact with its known part-20 weeks, they are hyperactive; by 24 weeks, the mice
develop urinary incontinence and decreased locomotor ner, LANP, and produces all the neurobehavioral and
unique pathologic features observed in 82Q mice. Itactivity, which progresses to akinesia in 4 to 5 weeks.
Once volitional movements cease, the mice do not re- wields the same pathogenicity as full-length expanded
ataxin-1, despite its inability to aggregate. Therefore,spond to sensory stimuli and die within a week. Striatal
degeneration, including human HD-like apoptosis and although nuclear localization of ataxin-1 is necessary,
nuclear aggregation of ataxin-1 is not required to initiategliosis, becomes evident during the hypokinetic phase.
Apoptosis also occurs in other areas typically affected pathogenesis in transgenic mice.
It remains unclear whether NIs are mere epiphenom-in HD, supporting the notion that selective neuronal vul-
nerability requires the context of full-length huntingtin. ena, beneficial to the cell, or participants in disease
progression. The findings of Cummings et al. (1998) thatFurthermore, transgenic mice expressing full-length HD
develop most of the phenotypic features at a much later NIs stain positively for the proteasome and molecular
chaperones suggests that they contain misfolded pro-time (20 weeks) than R6/2 mice (9 weeks), even though
the former have much higher levels of huntingtin ex- teins targeted for proteolysis; enhancing molecular
chaperone or proteasome activities may facilitate pro-pression.
In sum, the expanded polyglutamine tracts by them- cessing of the mutant proteins and provide an opportu-
nity for therapeutic intervention.selves wreak havoc, perhaps by misfolding or otherwise
disrupting nuclear functions. The size of these frag- Polyglutamine Toxicity in the Context of Proper
Spatial and Temporal Expressionments, usually ,50 kDa, likely facilitates their transport
into the nucleus; this would explain the high toxicity of It was now established that overexpression of mutant
proteins induced neurodegeneration in mice. The nexttruncated ataxin-3, the 3% fragment of huntingtin, and
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logical step was to determine whether expressing near-
endogenous levels of the proteins would prove patho-
genic.
Hodgson and colleagues (1999) generated HD trans-
genic mice that replicate the disease-causing mutation
in the same developmental and tissue-specific pattern
seen in human HD patients. They used yeast artificial
chromosomes (YACs) with the complete human HD lo-
cus carrying 18, 46, and 72 CAG repeats (corresponding
to normal, adult-onset-, and juvenile-onset-causing
tracts in humans) to create the so-called YAC18, YAC46,
and YAC72 lines. No developmental, neurobehavioral,
or pathological abnormalities are apparent in YAC18 and
YAC46 mice, but the YAC72 mice become hyperactive.
Both YAC46 and YAC72 mice develop progressive elec-
trophysiological dysfunction. Interestingly, the YAC72
mice show these changes prior to nuclear localization of
huntingtin. Immunostaining with an N-terminal antibody
reveals increased huntingtin expression in striatal neu-
ron nuclei; hyperchromasia and striatal atrophy, but no
NIs, are visible by EM.
At 6 months, YAC72 mice show NMDA receptor hyper-
activity, providing in vivo evidence of excitotoxicity in
early HD pathogenesis. At 10 months, neither YAC46
nor YAC72 mice showed long-term potentiation (LTP)
after-high frequency stimulation at Schaeffer collaterals.
To explain this puzzling result, the authors note that
increased NMDA receptor function would lead to ele-
Figure 1. Model for the Pathogenesis of Polyglutamine Diseasesvated calcium influx during synaptic transmission and
that increases in intracellular calcium levels correlate
with calcium-dependent desensitization of NMDA re-
itation suggest that the mice may be unable to sustainceptors. Hodgson et al. (1999) speculate, then, that dur-
neurotransmission during repetitive stimulation. Al-ing high-frequency stimulation, the NMDA receptors
though some of the phenotypic changes do not directlymay be inactivated by the high calcium influx, leading to
correlate with an HD phenotype, alterations in synaptic
loss of LTP in the mutant mice. The electrophysiological
plasticity and subtle emotional disturbances may pre-
abnormalities precede any neurobehavioral or neuro-
cede the motor and cognitive abnormalities typical of HD.
pathologic changes. Although the time at which these
A review of the various mouse models makes it clear
abnormalities first appear needs to be determined, the that appropriate spatial and temporal expression of a
data suggest that cytoplasmic functions (e.g., neuro- full-length protein with an expanded glutamine tract is
transmitter behavior and calcium regulation) are af- insufficient to produce overt phenotypes. Mice that
fected early in HD pathogenesis. Translocation of hun- manifest symptoms paralleling human disease (SCA1/
tingtin to the nucleus is evident only in the medium spiny B05, HD full-length transgenics) typically overexpress
neurons, which are susceptible to neurodegeneration; the mutant protein. From this, we infer that pathogenesis
this may account for the selective neuronal vulnerability is, at least in part, a function of two factors: mutant
seen in HD. protein levels and the amount of time a neuron is ex-
The most accurate mouse models for HD or other posed to the mutant protein (a matter of decades in
polyglutamine diseases should be those carrying CAG humans).
expansions within the endogenous genetic locus, i.e., Remaining Questions and Future Directions
knockins. Two such mouse mutants carrying expanded The above mouse models strongly support the notion
CAG repeats of different lengths in the mouse Hd locus that polyglutamine pathogenesis is caused by some
were generated by gene targeting. One line carrying 50 toxic function gained by the mutant protein as a result
CAG repeats has developed no neurological, pathologi- of the expanded CAG repeat. Selective neuronal vulner-
cal, or physiological changes, although the mutant pro- ability may be determined by the protein context of the
tein is expressed at wild-type levels and rescues the expanded polyglutamine tract and the level of protein
embryonic lethality of the Hd null mutation (White et in those cells. Mutant proteins may be abnormally pro-
al., 1997). In a second allele of HD knockin mice, an cessed or interact abnormally with other proteins, which
expansion of 72±80 CAG repeats was introduced into presumably contribute to selective neuronal dysfunction
the Hd locus (Shelbourne et al., 1999; Usdin et al., 1999). and degeneration (Figure 1).
Extensive analysis revealed few abnormalities besides Is the pathogenesis of all polyglutamine disorders me-
aggressive behaviors in 3-month-old mutant mice and diated by the same mechanism(s)? The answer is most
impaired LTP at Schaeffer collateral±CA1 synapses. Re- likely ªyes and no.º Protein misfolding and turnover
seem to be shared features, since glutamine tractduced posttetanic potentiation and paired-pulse facil-
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4567.can now be carried into mouse models to determine
whether these modifications occur in vivo. Likewise, the
putative involvement of the ubiquitin±proteasome path-
way might be investigated by mating the polyglutamine
mouse models with mice that have deficiencies in this
pathway or, conversely, with transgenic mice overex-
pressing factors within the pathway. Most importantly,
mouse models allow the study of early phenotypic
changes for which patient material is seldom available.
Gene chips and other array technologies should prove
invaluable for finding transcriptional changes early in
the disease process. Characterizing changes that occur
prior to any pathological events will greatly expand our
knowledge of the molecular mechanisms that cause
neurodegeneration in polyglutamine diseases.
